List of FDA Approved Stem Cell Therapies & Drugs – The Niche

In the past many of us have wished there was a list of FDA-approved stem cell therapies. Patients and fellow scientists often asked me, but I couldnt find a list.

As a result, the generic answer was, the FDA has approved umbilical cord blood therapies for cancer or immune disorders. Also, bone marrow transplantation, while not formally approved, is essentially an approved therapy.

Today we have more information and the goal of this post is to fill you in on where things stand.

Its encouraging.

FDA and cell therapies | List of diseases treated by stem cells | Key Context | Cell & Gene Therapies | List of FDA approved therapies 2022 | FDA approved stem cell clinics?| References

Other than what I mentioned above, there was nothing else approved that was an actual stem cell therapy. There were, however, cellular therapies approved even if not related to stem cells. In a way these fit into the broader category of regenerative medicine.

Note that you can watch me discuss this post in a new YouTube Video below.

What about today in 2022? Before we get to the approved products, I made a short list of the diseasestreated by stem cells.

Note that only very specific products matched with specific forms of these diseases have the FDA OK. For instance just because damaged cartilage is on the list doesnt mean anything goes. Theres no approval to treat it with fat stem cells, bone marrow, umbilical cord cells or exosomes.

The list of diseases has been growing. What about the products?

We need to turn to the FDA itself for the clearest answer on where things stand now.

Too often stem cell clinics claim that what they offer is FDA approved. In actuality at best what some of them sell is not FDA approved, but rather technically compliant with the rules for 361 products. What this means in English is that the products are not regulated as drugs.

So what does the FDA have to say about what they have approved?

In mid-2020, they issued an advisory, Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. In it they wrote:

Stem cell products are regulated by FDA, and, generally, all stem cell products require FDA approval. Currently, the only stem cell products that are FDA-approved for use in the United States consist of blood-forming stem cells (also known as hematopoietic progenitor cells) that are derived from umbilical cord blood. These products are approved for use in patients with disorders that affect the production of blood (i.e., the hematopoietic system) but they are not approved for other uses.

This fits with the general boilerplate some of us in the stem cell field have used, as noted earlier.

Note that, of course, the US and the FDA are not the only ones in this arena. The Alliance for Regenerative Medicine has what we might call an international list of cleared cell and gene therapies here.They are a great organization.

The good news today is that the agency has an actual list that is publicly available. Even better news is that there are more approved cell therapies than last time I tried to tackle this topic.

An interesting side note is that the agency for several years now has been combining together cell and gene therapies into one category. This is also reflected in their Regenerative Medicine Advanced Therapy (RMAT) designation program, which contains both types. RMATs still have to go through the trial approval process but get special consideration. You can see a help infographic below that my intern Mina made of the clinical trial approval process.

The formal FDA list of approved drugs made from stem cells is called, appropriately enough, Approved Cellular and Gene Therapy Products.

The current list is up to date as of September 1, 2022. Im going to update this post as the agency updates their list. Its interesting to speculate on how different this list might be in as short as 5 years given the exciting clinical trials that are ongoing now. In 10 years I predict its going to be a much longer list.

What about list of FDA approved stem cell clinics?

Such a list doesnt exist.

Why?

The reason is because no clinics have FDA approval. While some clinics sell stem cells that dont need formal FDA drug approval, most need that approval and yet dont have it.

View original post here:
List of FDA Approved Stem Cell Therapies & Drugs - The Niche

Stem cell therapy side effects & risks: infections, tumors & more

What are the possible stem cell therapy side effects of going to an unproven clinic? This is a common question I get asked. Most often it is asked by patients who reach out.

Check out the YouTube video below on our stem cell channel. If you like such videos please subscribe to our channel.

Many clinics have said over the years to potential customers that the worst that can happen is that the stem cells wont work.

We know this isnt true and its irresponsible.

Anything that has the potential to help a medical condition also poses some risks of harm. For this reason, its important to discuss potential stem cell therapy side effects. In this case I am focusing on the risks primarily associated with unproven stem cell clinics. Not for established methods like bone marrow transplantation.

Recent publications in journals including one by my colleague Gerhard Bauer and a special report by The Pew Charitable Trust have helped clarify risks. Gerhards paper presents the types of side effects that appear more common after people go to stem cell clinics. After closely following this area for a decade I was familiar with many of the examples of problems. However, some were new to me.

One of the highest profiles examples of bad outcomes was the case where three people lost their vision due to stem cells injected by a clinic.See image below of one set of damaged eyes. More on that case at the end of the post.

Why do stem cells pose risks?

Stem cells are uniquely powerful cells.

By definition they can both make more of themselves and turn into at least one other kind of specialized cells. This latter process is called differentiation. That former ability to make more of themselves is called self-renewal.

The most powerful stem cells are totipotent stem cells that can literally make any kind of differentiated cell. The fertilized human egg is the best example of a cell having totipotency. Next in the power line are pluripotent stem cells including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). Adult stem cells are multipotent. The best type of stem cell depends on the condition that is trying to be treated. The best type may not be the most powerful.

In any case, the power of stem cells is a main reason they also pose risks. These cells are not always easy to control and misdirected power can do harm.

Let me explain and start with the side effect that seems scariest to most.

If someone injects a patient with stem cells, its possible that the self-renewal power of stem cells just wont get shut off. In that scenario the stem cells could drive formation of a tumor or even cancer. Note that tumors are not always malignant whereas cancer is always malignant.

Why wouldnt a transplanted stem cell always eventually hit the brakes on self-renewal? It could be that the stem cell has one or more mutations. For any stem cells grown in a lab, within the population of millions of cells in a dish, there are going to be at least a few with mutations that crop up. Thats just the way it goes with growing cells in a lab.

Even stem cells not grown in the lab have the same spectrum of mutations as the person they were isolated from. It may seem weird to think about, but we all have some mutations.

When someone like a clinic person tells us that theres a risk to you thats a one in a million chance it doesnt sound that bad. However, with cells being injected into a person in theory all it takes is one cell out of a million cells in a syringe with a couple really bad mutations to potentially cause disaster. Research suggests it takes more than one cell with cancer-causing potential to make a tumor in experiments in the lab, but in actual people we just dont know. Many cancers may arise from one stem cell gone awry. If a clinic injects 50 or 100 million cells, a one-in-a-million rate of dangerous cells means that 50-100 such cells end up in the patient.

The odds are far lower for cells never grown in a lab to cause a tumor, but its still possible. Oddly, its possible that receiving someone elses stem cells (we call this allogeneic) might pose a lower cancer risk because your immune system is going to see those cells as foreign from the start.

But some stem cells, especially those with mutations, might be able to somewhat fly under the radar of the immune system to some extent even if they are from another person. This could allow them to grow into a tumor. The Pew report does a nice job of summarizing risks and there are several reports of tumors.

The possibility of infections after stem cell injections is another risk that is often discussed. Infections from injections of stem cells or other materials like PRP are probably the most common type of side effect. Bacteria can either sometimes already be in the product that is injected or can be introduced by poor injection or preparation methods by the one doing the procedure.

The distributor Liveyon had a product contaminated with bacteria that sickened at least a dozen people who were hospitalized. Some of them ended up in the ICU. A few may even have permanent issues.

Clinics using excellent procedures and products should have a low risk of infection more similar to getting any kind of invasive procedure even unrelated to stem cells.

Many preparations of stem cells sold at stem cell clinics these days are made from fat tissue or birth-related materials. I put stem cells in quotes because most fat and birth-related preparations only contain a small population of true stem cells.

In the case of adipose biologics, they mostly consist of a mixture of a dozen or so other kinds of cells found in fat.

The injections of fat cells are most often made IV right into the bloodstream. Fat cells just live in fat so they arent supposed to be floating around in your blood. As a result, after IV injection, many fat cells are thought to get killed right away.

Others end up landing in the lungs, where many are also probably meeting their doom. However, during this process of wiping out the fat cells it is possible that clots can start forming. Maybe the fat cells form small clots in the blood before they even get into the lungs. Either way, if the clots grow and are big enough, patients can get pulmonary emboli.

The same kind of risk may apply to IV injections or nebulizer inhalations of other kinds of stem cells.

There are other possible risks to stem cell injections too.

I wrote a post about possible graft versus host disease in stem cell recipients. This would only happen in people receiving someone elses stem cells. Its not clear if GvHD is something that happens to patients after going to clinics.

Beyond outright tumor formation it is also possible that stem cells will turn into an undesired or even dangerous tissue type. The example that comes to mind is the practice mentioned earlier of some clinics injecting fat cells into peoples eyeballs. What seems to have happened in some cases is that the mesenchymal cells (MSCs) that were injected turned into scar tissue, which caused retinal detachment. Unfortunately, what are called MSCs by some clinics can mostly consist of close relatives of fibroblasts or in some cases may even largely consist of fibroblasts. Fibroblasts are good at making scar tissue under some circumstances and that can create pull on surrounding tissues including the retina if inside the body.

Specific kinds of stem cells or routes of administration may pose unique risks as well. For instance, intranasal administration of stem cells is getting popular with unproven clinics and could lead to stem cells ending up in the brain.

Other products in the regenerative sphere that are not stem cells may be risky as well for various reasons. For instance, an exosome product harmed quite a few people in Nebraska.Some problems may relate to product contamination.

There have also been cases of unusual immune reactions to stem cell injections.

Finally, stem cells also pose unknown risks because of their power. We just dont have long-term follow up data to have a clear sense of risks.

Read the original here:
Stem cell therapy side effects & risks: infections, tumors & more

Global Nerve Repair and Regeneration Devices Market to Reach $12.9 Billion by 2027 – Yahoo Finance

ReportLinker

Abstract: Whats New for 2022?? Global competitiveness and key competitor percentage market shares. Market presence across multiple geographies - Strong/Active/Niche/Trivial.

New York, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nerve Repair and Regeneration Devices Industry" - https://www.reportlinker.com/p05957490/?utm_source=GNW

Online interactive peer-to-peer collaborative bespoke updates

Access to our digital archives and MarketGlass Research Platform

Complimentary updates for one yearGlobal Nerve Repair and Regeneration Devices Market to Reach $12.9 Billion by 2027 - In the changed post COVID-19 business landscape, the global market for Nerve Repair and Regeneration Devices estimated at US$6.6 Billion in the year 2020, is projected to reach a revised size of US$12.9 Billion by 2027, growing at aCAGR of 10% over the period 2020-2027. Neurostimulation & Neuromodulation Devices, one of the segments analyzed in the report, is projected to record 9.7% CAGR and reach US$10.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Biomaterials segment is readjusted to a revised 11.7% CAGR for the next 7-year period. - The U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 13% CAGR - The Nerve Repair and Regeneration Devices market in the U.S. is estimated at US$2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2 Billion by the year 2027 trailing a CAGR of 13% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.7% and 8.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.2% CAGR.

Select Competitors (Total 61 Featured) Abbott Laboratories, Inc. AxoGen, Inc. Boston Scientific Corporation Integra LifeSciences Corporation LivaNova, PLC Medtronic plc NeuroPace, Inc. Nevro Corporation. Orthomed S.A.S. Polyganics B.V. Stryker Corporation Synapse Biomedical Inc. Synovis Micro Companies Alliance, Inc.

Read the full report: https://www.reportlinker.com/p05957490/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY 1. GLOBAL MARKET OVERVIEW Impact of Covid-19 and a Looming Global Recession 2020 Marked as a Year of Disruption & Transformation World Economic Growth Projections (Real GDP, Annual % Change) for 2019 to 2022 Global Nerve Repair & Regeneration Market Buckles under COVID- 19 Strain Covid-19 Patients in Prone Position Suffering Nerve Damage Bodes Well for Market Growth Nerve Repair and Regeneration Market Set for a Robust Growth Neurostimulation & Neuromodulation Devices Hold Commanding Slot in Nerve Repair & Regeneration Market Biomaterials to Exhibit Rapid Growth Nerve Repair and Regeneration Market by Application US and Europe Dominate the Market Asia-Pacific and other Emerging Regions Display Impressive Growth Potential Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS High Incidence of Neurological Disorders: A Key Market Driver Annual Incidence of Adult-Onset Neurologic Disorders in the US Effects of COVID-19 on the Nervous System Sheds Focus on Neuromodulation Applications Increasing Cases of Peripheral Nerve Injuries Drive the Nerve Repair and Regeneration Market Growing Number of Vehicular Accidents Drive the Peripheral Nerve injuries Repair Market Rising Geriatric Population and Subsequent Growth in Prevalence Of Neurological Disorders Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 Growing Incidence of Neurodegenerative Diseases Propels the Market for Deep Brain Stimulation Devices Global Alzheimers Prevalence by Age Group Diagnosed Prevalence Cases of Parkinson?s Disease Across Select Countries Global DBS Market by Leading Player (2020E): Market Share Breakdown of Revenues for Medtronic, Boston Scientific, and Abbott Select Available Deep Brain Stimulation Devices Available in the Market Intensified Research Activity Across Various Neural Disciplines Induces Additional Optimism Stem Cell Therapy: A Promising Avenue for Nerve Repair and Regeneration Increasing Cases of Epilepsy Drives the Demand for Vagus Nerve Stimulation Devices Epilepsy Incidence by Type (2019): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy Spinal Cord Injuries Propel the Demand for Spinal Cord Stimulation Devices Recent Developments in Spinal Cord Injury Treatment Biomaterials (Nerve Conduits and Nerve Wraps) to Witness Rapid Growth New Biomaterials Pave the Way for Innovative Neurodegeneration Therapies Role of Nerve Conduits in the Treatment of Peripheral Nerve Injury Innovative Nerve Conduits from Stryker TENS (Transcutaneous electrical nerve stimulation devices) Market Witnesses Rapid Growth Non-Invasiveness of TMS (Transcranial Magnetic Stimulation) Propelling the adoption of TMS devices Nerve Grafts for Bridging Larger Nerve Gaps Role of Nerve Grafting in Treatment of Peripheral Nerve Injuries FDA-approved Nerve Tubes for Peripheral Nerve Repair

4. GLOBAL MARKET PERSPECTIVE Table 1: World Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Nerve Repair and Regeneration Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Nerve Repair and Regeneration Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for Neurostimulation & Neuromodulation Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Neurostimulation & Neuromodulation Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Neurostimulation & Neuromodulation Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for Biomaterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Biomaterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Biomaterials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for Neurostimulation & Neuromodulation Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Neurostimulation & Neuromodulation Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Neurostimulation & Neuromodulation Surgeries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for Neurorrhaphy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Neurorrhaphy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Neurorrhaphy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for Nerve Grafting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Nerve Grafting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Nerve Grafting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 Impact of Covid-19 and a Looming Global Recession

III. MARKET ANALYSIS

UNITED STATES Nerve Repair and Regeneration Devices Market Presence - Strong/ Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) Table 28: USA Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 29: USA Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 30: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2021 & 2027

Table 31: USA Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2021 & 2027

Table 34: USA Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2021 & 2027

CANADA Table 37: Canada Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 39: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2021 & 2027

Table 40: Canada Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 41: Canada Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2021 & 2027

Table 43: Canada Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 45: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2021 & 2027

JAPAN Nerve Repair and Regeneration Devices Market Presence - Strong /Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) Table 46: Japan Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 47: Japan Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 48: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2021 & 2027

Table 49: Japan Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 50: Japan Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2021 & 2027

Table 52: Japan Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 53: Japan Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 54: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2021 & 2027

CHINA Nerve Repair and Regeneration Devices Market Presence - Strong /Active/Niche/Trivial - Key Competitors in China for 2022 (E) Table 55: China Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 56: China Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 57: China 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2021 & 2027

Table 58: China Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 59: China Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: China 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2021 & 2027

Table 61: China Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 62: China Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 63: China 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2021 & 2027

EUROPE Nerve Repair and Regeneration Devices Market Presence - Strong/ Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) Table 64: Europe Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 65: Europe Historic Review for Nerve Repair and Regeneration Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 66: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027

Table 67: Europe Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 68: Europe Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 69: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2021 & 2027

Table 70: Europe Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 71: Europe Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2021 & 2027

Table 73: Europe Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2021 & 2027

FRANCE Nerve Repair and Regeneration Devices Market Presence - Strong/ Active/Niche/Trivial - Key Competitors in France for 2022 (E) Table 76: France Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 77: France Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 78: France 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2021 & 2027

Table 79: France Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 80: France Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 81: France 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2021 & 2027

Table 82: France Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 83: France Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 84: France 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2021 & 2027

GERMANY Nerve Repair and Regeneration Devices Market Presence - Strong/ Active/Niche/Trivial - Key Competitors in Germany for 2022: (E) Table 85: Germany Recent Past, Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 86: Germany Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 87: Germany 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2021 & 2027

The rest is here:
Global Nerve Repair and Regeneration Devices Market to Reach $12.9 Billion by 2027 - Yahoo Finance

Gene Synthesis Market to Witness Impressive Expansion of USD 9,121.31 Million with a Growing Compound Annual Growth Rate of 22.9% by 2029 – Yahoo…

Data Bridge Market Research

Bacterial and viral diseases are rapidly expanding due to the rising prevalence of infectious diseases worldwide. As a result, the demand for novel and effective therapies has increased to fight against such deadly diseases

HOUSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Data Bridge Market Research has recently published a Report, titled, "Global Gene Synthesis Market" The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segments, Porter's Five Forces analysis, and competitive landscape. All the data and statistics provided in this market report are backed up by the latest and proven tools and techniques such as SWOT analysis and Porter's Five Forces Analysis. With the latest and updated market insights mentioned in the report, businesses can concentrate to enhance their marketing, promotional, and sales strategies.

Gene synthesis is the process of creating artificial genes in a lab setting using synthetic biology. The generation of recombinant proteins is one of the numerous applications of recombinant DNA technology, where gene synthesis is emerging as a key instrument. The traditional methods of cloning and mutagenesis are quickly being replaced by de novo gene synthesis, which also enables the production of nucleic acids for which there is no template.

The global gene synthesis market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 22.9% in the forecast period of 2022 to 2029 and is expected to reach USD 9,121.31 million by 2029 from USD 1,726.26 million in 2021.

Download the Exclusive Sample of the Gene Synthesis Market Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-gene-synthesis-market

Market Synopsis: -

Gene synthesis refers to the chemical synthesis of DNA strand base-by base. Unlike DNA replication that occurs in cells or by Polymerase Chain Reaction (PCR), gene synthesis does not require a template strand. Rather, gene synthesis involves the step-wise addition of nucleotides to a single-stranded molecule, which then serves as a template for creating a complementary strand. Gene synthesis is the fundamental technology upon which the field of synthetic biology has been built.

Story continues

Some of the major players operating in the Gene Synthesis market are

Recent Development

In December 2020, Twist Bioscience launched clonal-ready gene fragments so as to complete the offering of genes. The fragments launched can be used with adapters or without adapters in order to build up the perfect clones. The clonal-ready gene fragments are compatible with the protein expression pathways, enzyme engineering, and gene expression, among others.

In 2020, according to an article published in an ACS journal, a total estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths were reported worldwide. This suggests that cancer coverage is suboptimal, and there is a great need to implement high cancer coverage all over the world.

Grab Full PDF Research Report @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-gene-synthesis-market

Key Coverage in the Gene synthesis Market Report:

Detailed analysis of Gene synthesis Market by a thorough assessment of the technology, product type, application, and other key segments of the report

Qualitative and quantitative analysis of the market along with CAGR calculation for the forecast period

Investigative study of the market dynamics including drivers, opportunities, restraints, and limitations that can influence the market growth

Comprehensive analysis of the regions of the Gene synthesis industry and their futuristic growth outlook

Competitive landscape benchmarking with key coverage of company profiles, product portfolio, and business expansion strategies

Key Segmentation: Gene Synthesis Market

By Component

Synthesizers

Consumables

Software & services

By Gene Type

Standard gene

Express gene

Complex gene

Others

By Gene Synthesis Type

Gene library synthesis

Custom gene synthesis

By Application

Synthetic biology,

Genetic engineering,

Vaccine design,

Therapeutics antibodies

Others

By Method

By End User

Academic & research institutes,

Diagnostics laboratories,

Biotech & pharmaceutical companies

Others

By Distribution Channel

Direct tender

Online distribution

Third party distributors

Get a Detailed Summary of the Research Report @ https://www.databridgemarketresearch.com/reports/global-gene-synthesis-market

Opportunities

Healthcare expenditure has increased worldwide as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure.

Also, the strategic initiatives taken by key market players will provide structural integrity and future opportunities for the medical device testing market in the forecast period of 2022-2029.

Regional Analysis/Insights

The gene synthesis market report is analyzed, and market size insights and trends are provided by the country, component, gene type, gene synthesis type, application, method, end user, and distribution channel, as referenced above.

North America dominates the gene synthesis market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the rising need for the verification and validation of gene synthesis processes in the region, and rapid research development is boosting the market

Countries Studied:

North America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)

Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)

Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)

Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Table of Contents:

1 Introduction

2 Market Segmentation

3 Executive Summary

4 Premium Insights

5 Global Gene Synthesis Market: Regulations

6 Market Overview

7 Global Gene Synthesis Market, By Component

8 Global Gene Synthesis Market, By Gene Type

9 Global Gene Synthesis Market, By Gene Synthesis Type

10 Global Gene Synthesis Market, By Application

11 Global Gene Synthesis Market, By Method

12 Global Gene Synthesis Market, By End User

13 Global Gene Synthesis Market, By Distribution Channel

14 Global Gene Synthesis Market, By Region

15 Global Gene Synthesis Market: Company Landscape

16 SWOT Analyses

17 Company Profile

18 Questionnaire

19 Related Reports

For More Insights, Grab TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-gene-synthesis-market

Browse Related Reports:

North America Gene Synthesis Market, By Component (Synthesizer, Consumables, and Software & Services), Gene Type (Standard Gene, Express Gene, Complex Gene and Others), Gene Synthesis Type (Gene Library Synthesis, and Custom Gene Synthesis), Application (Synthetic Biology, Genetic Engineering, Vaccine Design, Therapeutics Antibodies, and Others), Method (Solid Phase Synthesis, Chip-Based DNA Synthesis, and PCR-Based Enzyme Synthesis), End User (Academic & Research Institutes, Diagnostics Laboratories, Biotech & Pharmaceutical Companies, and Others), Distribution Channel (Direct Tender, Online Distribution, and Third Party Distributors), Industry Trends and Forecast to 2029 https://www.databridgemarketresearch.com/reports/north-america-gene-synthesis-market

Europe Gene Synthesis Market, By Component (Synthesizer, Consumables, and Software & Services), Gene Type (Standard Gene, Express Gene, Complex Gene and Others), Gene Synthesis Type (Gene Library Synthesis, and Custom Gene Synthesis), Application (Synthetic Biology, Genetic Engineering, Vaccine Design, Therapeutics Antibodies, and Others), Method (Solid Phase Synthesis, Chip-Based DNA Synthesis, and PCR-Based Enzyme Synthesis), End User (Academic & Research Institutes, Diagnostics Laboratories, Biotech & Pharmaceutical Companies, and Others), Distribution Channel (Direct Tender, Online Distribution, and Third Party Distributors), Industry Trends and Forecast to 2029 https://www.databridgemarketresearch.com/reports/europe-gene-synthesis-market

Asia-Pacific Gene Synthesis Market, By Component (Synthesizer, Consumables, and Software & Services), Gene Type (Standard Gene, Express Gene, Complex Gene and Others), Gene Synthesis Type (Gene Library Synthesis, and Custom Gene Synthesis), Application (Synthetic Biology, Genetic Engineering, Vaccine Design, Therapeutics Antibodies, and Others), Method (Solid Phase Synthesis, Chip-Based DNA Synthesis, and PCR-Based Enzyme Synthesis), End User (Academic & Research Institutes, Diagnostics Laboratories, Biotech & Pharmaceutical Companies, and Others), Distribution Channel (Direct Tender, Online Distribution, and Third Party Distributors), Industry Trends and Forecast to 2029 https://www.databridgemarketresearch.com/reports/asia-pacific-gene-synthesis-market

Middle East And Africa Gene Synthesis Market, By Component (Synthesizer, Consumables, and Software & Services), Gene Type (Standard Gene, Express Gene, Complex Gene and Others), Gene Synthesis Type (Gene Library Synthesis, and Custom Gene Synthesis), Application (Synthetic Biology, Genetic Engineering, Vaccine Design, Therapeutics Antibodies, and Others), Method (Solid Phase Synthesis, Chip-Based DNA Synthesis, and PCR-Based Enzyme Synthesis), End User (Academic & Research Institutes, Diagnostics Laboratories, Biotech & Pharmaceutical Companies, and Others), Distribution Channel (Direct Tender, Online Distribution, and Third Party Distributors), Industry Trends and Forecast to 2029 https://www.databridgemarketresearch.com/reports/middle-east-and-africa-gene-synthesis-market

Gene Synthesis Software Market, By Application (Research and Development Activities, Diagnostics, Therapeutics, Others) End User (Academic and Research Institutes, Biotech and Pharmaceutical Companies, Diagnostic Laboratories, Others), Synthesis Type (Gene Library Synthesis, Custom Gene Synthesis), Method (Solid Phase Synthesis, Chip-Based DNA Synthesis, PCR-Based Enzyme Synthesis), Country https://www.databridgemarketresearch.com/reports/global-gene-synthesis-software-market

Next Generation Sequencing (NGS) Market, By Product (Instruments, Consumables and Services), Applications (Diagnostics, Biomarker Discovery, Precision Medicine, Drug Discovery, Agriculture and Animal Research and Others), End User (Pharmaceutical & Biotechnology Companies, Research Centers & Academic and Government Institutes and Hospital & Clinics), Country https://www.databridgemarketresearch.com/reports/global-next-generation-sequencing-ngs-market

Nerve Regeneration and Repair Market, By Product (Neurostimulation and Neuromodulation Devices and Biomaterials), Indication (Failed Back Surgery Syndrome, Parkinson's disease, Urinary Incontinence, Epilepsy, Gastroparesis, Nerve Repair and Grafting), Application (Neurostimulation and Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting, and Stem Cell Therapy), End User (Hospitals and Clinics and Ambulatory Surgical Centers) https://www.databridgemarketresearch.com/reports/global-nerve-regeneration-and-repair-market

Branded Generics Market, By Product Type (Value-Added Branded Generics, Trade Named Generics), Therapeutic Application (Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics and Anti-Inflammatory, Others), Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptic, Others), Consumption Type (Oral, Parenteral, Topical, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) https://www.databridgemarketresearch.com/reports/global-branded-generics-market

Prenatal Genetic Testing Market, By Technology {Diagnostics Methods, Screening Methods}, Screening Techniques (Carrier Screening, Sequential Screening, and Maternal Serum Quad Screening), Diseases (Alzheimers Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntingtons Disease, Rare Diseases, Other Diseases), End User (Hospitals, Clinics, Diagnostic Centers), Product (Products, Consumables, Assay Kits And Reagents, Disposables, Instruments, Next Generation Sequencing Systems, Polymerase Chain Reaction Instruments, Microarrays, Ultrasound Devices, Other Instruments, Services) https://www.databridgemarketresearch.com/reports/global-prenatal-genetic-testing-market

Tissue Regeneration Market, By Technology (Cell Therapy, Stem Cell Therapy, Stem Cell Sources, Tissue Vascularization, Cell Culturing and Others), Raw Material (Synthetic, Genetically modified and Biological), Application (Cardiovascular, Oncology, Dermatology, Orthopedic, Neurology, Ophthalmology and Others), End-User (Hospital & Diagnostic Centres, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Others) https://www.databridgemarketresearch.com/reports/global-tissue-regeneration-market

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us: -

Data Bridge Market Research

US: +1 888 387 2818

Link:
Gene Synthesis Market to Witness Impressive Expansion of USD 9,121.31 Million with a Growing Compound Annual Growth Rate of 22.9% by 2029 - Yahoo...

Promaxo Announces Six System Sales in the Third Quarter 2022 – The Bakersfield Californian

OAKLAND, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Promaxo, Inc. (Promaxo or the Company), a medical imaging, robotics, and AI technology company, today announced the sale of six systems in the United States in the third quarter ending September 30, 2022. The system sales included both operating lease and revenue share agreements with physician practices in Florida, New Jersey, and Texas. Promaxos single-sided MRI with AI based imaging system, FDA cleared for in-office use, empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo MRI system.

In the third quarter, North Florida Urology Associates in Gainesville, FL, Avant Concierge Urology in Winter Garden, FL, Urology Center of Winter Park in Winter Park, FL, Sovereign Health System in Jersey City, NJ, Jersey Urology Group in Somers Point, NJ, and Urology America MSO in Austin, TX entered into agreements with Promaxo.

Dr. Sijo Parekattil, Director of Avant Concierge Urology and Associate Professor of Urology at the University of Central Florida said, Given our focus on leveraging the latest technologies, robotics and microsurgery in our urology practice, incorporating the Promaxo MRI system into our programs was a natural and synergistic next step. Coupled with the flexibility of commercial partnership programs offered by Promaxo, we are impressed with the ease at which we place the system in our office and with how quickly we begin to provide Promaxo MRI procedures to our patients.

With focused market penetration activities, we are pleased to add six new physician practices to Promaxos growing clinical network in the United States, maintaining our growth momentum through the third quarter 2022, said Dr. Amit Vohra, Founder and CEO of Promaxo. We are committed to making MRIs more accessible for interventions, as we continue to partner with physician offices through our flexible sales and financing programs.

About Sovereign Health System

Sovereign Health System is a multi-specialty community healthcare system, with primary and specialty medical care provided by the physicians of the Sovereign Health Medical Group, in addition to outpatient care provided by Sovereign Health Urgent Care, Sovereign Health Cancer Care, and Sovereign Health SurgiCare. Sovereign Health Medical Group has ten urology practice locations in New Jersey.

About North Florida Urology Associates

North Florida Urology Associates is a medical practice with clinics in Ocala, Gainesville, and The Villages, Florida. With a focus on promoting mens health for over 36 years, the practice has raised awareness and led its field in treating conditions such as prostate cancer, erectile dysfunction, and kidney stones by leveraging leading technologies. The practice utilizes technologies such as HIFU, ErosWave, cryosurgery, shockwave therapy, and stem cell therapy to address and treat their patients needs.

About Avant Concierge Urology

Avant Concierge Urology is a Central Florida urology practice, specializing in the treatment of conditions related to the kidneys, urinary bladder, adrenal glands, urethra, and male reproductive organs. Avant offers personalized, best-in-class surgical treatment options, with the intent to minimize downtime, scarring, and expenses. With focus on offering latest technologies, including digital microsurgery, Avant is the first and only in-office operator of the Karl STORZ 3D Vitom digital microsurgery system in the United States, offering patients a best-in-class surgery solution allowing for better precision and decreased recovery time.

About Jersey Urology Group

Jersey Urology Group is a comprehensive urology practice in southern New Jersey, with a team of top urology doctors in New Jersey offering patients state-of-the-art technologies and innovative therapies for the treatment of all urologic conditions. Urology services include treating kidney stones, prostate problems, infertility, and other complex urological issues.

About Urology Center of Winter Park

Urology Center of Winter Park, centrally located in Florida at Winter Park, utilizes state of the art, minimally invasive urological procedures in the diagnosis and treatment of all types of urological issues. The practice provides medical solutions dedicated to all aspects of urological care with the latest in minimally, and non-invasive techniques to reduce pain and hasten recovery. Services include urology, urologic surgery and urologic oncology.

About Urology America MSO

Urology America is a national, best-in-class urology platform founded in Central Texas by Urology Austin physicians and Gauge Capital. Urology Americas mission is to build a platform that provides unparalleled support to providers and care team, to deliver exceptional and comprehensive urological care, with compassion and service that exceeds expectations. Urology America is built with a focus on achieving returns through innovation and revenue growth. This includes drawing on expertise and collective experience to develop new services where applicable.

About Promaxo, Inc.

Promaxo was founded by a team of entrepreneurs and healthcare innovators to develop a minimally-invasive and patient-centric MRI and robotic platform. Based in Oakland, California, and backed by over 200 patents, the Companys mission is to improve lives through state-of-the-art medical imaging, robotics and AI capabilities. With a compact and adaptable MRI, Promaxo is redefining the standard of care by improving the quality and speed of patient diagnosis and interventions. The Company has formed numerous long-term and strategic partnerships with investor groups and corporation as it drives commercialization of the Promaxo MRI system.

To learn more about the technology behind the MRI system and its scope, please visit: Promaxo.com.

LinkedIn: Promaxo

Twitter: @Promaxo

Facebook: Promaxo

Investors

Gilmartin Group

Vivian Cervantes

e: IR@promaxo.com

Link:
Promaxo Announces Six System Sales in the Third Quarter 2022 - The Bakersfield Californian

Stem Cell Therapy for Eye Disease: What You Need to Know

Avoid Unlicensed Clinics Offering Unapproved Stem Cell Therapy

Stem cell therapies are getting headlines for their potential to cure diseases, including those that affect vision. But an important message is missing: the therapies are not yet proven to be safe and effective for your eyes.

Stem cell treatments appear to offer hope to people with few options to recover vision. This includes people with forms of age-related macular degeneration (AMD), retinitis pigmentosa (RP), and Stargardt disease. Some clinics across the United States offer "stem-cell therapy" to people outside of clinical trials. But the Food and Drug Administration (FDA) has not approved the treatments they offer. These treatments often use unproven products that may be ineffective or dangerous. These products may carry serious risks, including tumor growth.

It is important that you know that there are no stem cell products approved by the FDA for eye disease right now. If you want stem cell therapy, look for a clinical trial and discuss the matter with your ophthalmologist. A clinic should not expect you to pay thousands of dollars for an unproven, unapproved therapy. Your health insurance will not cover the cost of an unapproved treatment.

Before agreeing to a stem cell treatment, ask yourself:

It is frustrating and frightening to face the loss of vision while waiting for potential treatments. However, choosing to pursue an unproven treatment in an unlicensed clinic is an unacceptable risk to your vision and your overall health.

The American Academy of Ophthalmology wants to reduce or eliminate unlicensed stem cell clinics in the United States. In June 2016, the Academy asked the FDA to tighten regulations and increase investigations into stem cell treatments given outside of clinical trials.

Go here to see the original:
Stem Cell Therapy for Eye Disease: What You Need to Know

How Does Stem Cell Therapy Work and What Are the Risks? | ISCRM

Human stem cells are essential for the growth and maintenance of our organs, bones, and systems. They are also amazing tools of discovery for scientists at the Institute for Stem Cell and Regenerative Medicine and researchers around the world studying how to stop diseases. However, predatory businesses across the country are misusing the term stem cells to market unapproved, unproven, and unsafe procedures that are often expensive and largely ineffective. Its important to understand what stem cell therapy really means.

Lets start by creating two categories of stem cell therapies approved (by the FDA) and unapproved. Whether a stem cell therapy is approved or unapproved has critical implications for the science, effectiveness, and safety of the procedure.

(In addition to blood stem cell transplants), the FDA lists a limited number of additional approved products on its website.)

More recently, hundreds of businesses around the country referring to themselves as clinics have begun marketing various versions of stem cell therapy that promise to help patients with serious conditions like Parkinsons disease and more common ailments like joint pain. In reality, most of these types of stem cell therapy do not use stem cells at all. Rather, they remove tissues that presumably contains adult stem cells from one body part and inject those cells into another part of the body.

Furthermore, there is no proof that any stem cell therapy offered by stem cell clinics is effective or safe. Unlike FDA-approved procedures, which are subject to years of rigorous trials, unapproved treatments marketed directly to patients are developed and performed with little oversight. While stem cell clinics often tout testimonials from satisfied customers, there has never been a large-scale clinical trial to demonstrate that the perceived benefits of a stem cell therapy arent the result of a placebo effect. In recent years, the FDA has begun to expand regulations and enforcement of these clinics.

Thanks to decades of data, we know much more about the effectiveness of blood stem cell transplants. We also know they are not instant cures. While the procedure itself only lasts a few hours, recovery can take weeks. During this period, patients are monitored closely by physicians and nurses for side effects and for evidence of recovery.

There are side effects associated with approved and unapproved stem cell therapies. The possible side effects of blood stem cell transplants are detailed on the Cancer.org website. Patients considering an unapproved stem cell therapy should be aware that these procedures carry serious risks and that these risks may not be managed by a qualified care team. Injecting even a persons own tissue in a different body part has resulted in severe illness and, in some cases, blindness.

Therapies offered by stem cell clinics come with financial risk as well. Because these procedures are generally not covered by insurance, people seeking treatment are required to pay large out-of-pocket fees with no guarantee of improved health.

In their advertising, stem cell clinics promise unsubstantiated relief or even cures for everything from knee pain to Parkinsons disease, often taking advantage of vulnerable individuals who may feel they have nowhere else to turn. In reality, there is no strong evidence to back up claims that any stem cell therapy works let alone has lasting benefits.

See the original post here:
How Does Stem Cell Therapy Work and What Are the Risks? | ISCRM

CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte – PR Newswire

SINGAPORE, Sept. 16, 2022 /PRNewswire/ --CellResearch Corporation, a Singapore-based biopharmaceutical company today announced it has successfully closed the first Phase I study in CorLiCyte, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at the University of Colorado, Anschutz Medical Campus and ClinImmune Cell and Gene Therapy.

CorLiCyte is in development for the treatment of a number of serious conditions, with a first target indication of treating diabetic foot ulcer (DFU). In the study protocol nine patients with chronic DFU were treated with CorLiCyte twice weekly for 8 weeks. None of the patients participating in the study experienced any treatment-related adverse events and all subjects saw a reduction in wound size during the treatment period.

"These results are encouraging and can be used to support further research with CorLiCyte in future studies, with the potential to address unmet medical needs in treatment of patients with chronic DFUs." said Cecilia Low-Wang, the lead investigator at the University of Colorado, Anschutz Medical Campus.

About CorLiCyte

CorLiCyte is a live mesenchymal stem cell therapy derived from human umbilical cord lining stem cells, with a proprietary optimised expression of cytokines, growth and cellular factors for the treatment of a number of serious health conditions. In addition to DFU, CRC is pursuing a range of potential indications at pre-clinical stage such as osteoarthritis, venous leg ulcers, chronic inflammatory and autoimmune conditions.

About CellResearch Corporation

CellResearch Corporation (CRC) was founded in 2002 as a contract research provider focusing on skin cells. In 2004, the company made the discovery that the umbilical cord lining of mammals was an abundant source of both mesenchymal and epithelial stem cells. Today, the company owns this technology through a family of patents and holds the rights to commercialise this technology in most major markets globally.

CellResearch Consumer Health (Formerly known as CALECIM Cosmeceuticals) is a wholly owned subsidiary of CRC and produces an innovative range of skin and hair care products using cord lining stem cell media to power its products. It is used in medical hair and aesthetic clinics for in-office treatments and as part of an at-home anti-aging skincare regime. It is distributed globally through over 600 aesthetic physicians and online via its own website. It has a key distribution partnership with Menarini Group across South East Asia.

CRC partner, Cordlife offers parents the opportunity to bank their child's umbilical cord tissue alongside their cord blood. Cordlife has what is believed to be the largest licensed bank of umbilical cord tissue globally. As cell therapies move into the clinic, Cordlife will have the ability to expand stem cells from a banked umbilical cord for autologous and donor-related uses.

Contact:

Business Development and Investor Relations: Xavier Simpson Tel: +65 8815 6139 Email: [emailprotected]

http://www.cellresearchcorp.com http://www.calecimprofessional.com

SOURCE CellResearch Corporation

Excerpt from:
CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte - PR Newswire

Nerve Repair and Regeneration Market Size Worth $12,514 – GlobeNewswire

New York, Sept. 02, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on Nerve Repair & Regeneration Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product {Neurostimulation & Neuromodulation Devices [Internal Neurostimulation Devices (Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, and Gastric Electrical Stimulation) and External Neurostimulation Devices (Transcutaneous Electrical Nerve Stimulation Devices, Transcranial Magnetic Stimulation Devices, Respiratory Electrical Stimulation Devices)] and Biomaterials [Nerve conduits, Nerve wraps, Nerve Connectors, and Other Biomaterials]} and Application {Neurostimulation & Neuromodulation Applications [Internal neurostimulation & neuromodulation and External neurostimulation & neuromodulation], and Nerve Repair & Regeneration Applications [Direct Nerve Repair/Neurorrhaphy (Epineural Repair, Perineural Repair, and Group Fascicular Repair), Nerve Grafting (Autografts, Allografts, and Xenografts), and Stem cell therapy]}, the global nerve repair & regeneration market size is projected to reach USD 12,514.06 million by 2028 from USD 6,607.71 million in 2021; it is expected to grow at a CAGR of 9.7% from 2022 to 2028.

Download Sample Brochure of Nerve Repair and Regeneration Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.theinsightpartners.com/sample/TIPHE100001254/

Nerve Repair and Regeneration Market Report Scope & Strategic Insights:

Global Nerve Repair & Regeneration Market: Competitive Landscape and Key Developments A few companies in the global nerve repair & regeneration market are Axogen Corporation, Boston Scientific Corporation, Integra LifeSciences, Medtronic, Abbott Laboratories, Stryker Corporation, Neuronetics, LivaNova PLC, Baxter, and Polyganics BV. The companies operating in the global nerve repair & regeneration market implement various growth strategies, such as product launches, expansions, and product upgrades. Similarly, several companies are implementing inorganic strategies such as acquisitions, collaboration, and partnerships.

Inquiry Before Purchase: https://www.theinsightpartners.com/inquiry/TIPHE100001254/

In Aug 2021, Checkpoint Surgical, Inc. launched the NeuroShield Chitosan Nerve Wrap to expand its intraoperative nerve care product line. The NeuroShield Wrap marks the company's first product in a planned line of chitosan-based biological implants to support nerve healing. Adding the product complements the existing product portfolio of Checkpoint Surgical, including the companys flagship Checkpoint Nerve Stimulator/Locator, the leading nerve stimulation device for intraoperative nerve protection and repair.

In Mar 2021, Abbott launched NeuroSphere Virtual Clinic in the US, a first-of-its-kind technology enabling patients to interact with physicians, ensure proper functionality and settings, and receive new treatment settings remotely as per requirement. The NeuroSphere Virtual Clinic can extend access to optimal treatment for patients with movement disorders or chronic pain who don't live near a care provider, who can not access care easily or are unable to visit a physician due to circumstances such as COVID-19.

The nerve repair and regeneration market growth is attributed to the growing incidence of nerve injuries and the high prevalence of neurological disorders, the growing geriatric population and rising prevalence of age-associated neurological disorders, and increasing funding by private and government organizations for research in neurology. However, the absence of trained professionals is hampering the growth of the global nerve repair & regeneration market.

Speak to Research Expert: https://www.theinsightpartners.com/speak-to-analyst/TIPHE100001254

Global Nerve Repair & Regeneration Market: Key Insights Future Trend Nerve repair and regeneration offers products such as neuromodulators & neurostimulation devices, and biomaterials. These devices treat neurodegenerative or traumatic disorders such as Parkinson's disease, Alzheimer's disease, sclerosis, multiple system atrophy, and amyotrophic lateral sclerosis. Therefore, market players are launching various products such as internal neurostimulation devices, external neurostimulation devices, nerve conduits, nerve wraps, nerve connectors, and other biomaterials to enhance the treatment output of nerve repair and regeneration.

A few of the recent developments related to the nerve repair and regeneration market are mentioned below:

In July 2022, Checkpoint Surgical launched the Checkpoint Edge Nerve Cutting Kit, expanding the strength of the intraoperative nerve care portfolio of the company. The Checkpoint Edge Nerve Cutting Kit is the first offering in the planned portfolio of nerve-specific instruments by Checkpoint Surgical, with further expansion planned in the future.

In April 2022, Boston Scientific Corporation received US Food and Drug Administration (FDA) approval for its latest image-guided programming software, Vercise Neural Navigator with STIMVIEW XT. The product is developed in collaboration with Brainlab AG. STIMVIEW XT allows physicians, in real-time, the capacity to visualize both stimulation modeling and lead placement of the brain anatomy of their patients having an essential tremor or Parkinsons disease.

In Mar 2022, Integra LifeSciences Holding Corporation launched the NeuraGen 3D Nerve Guide Matrix, which is a resorbable implant to repair peripheral nerve discontinuities. NeuraGen 3D is a nerve repair product specifically engineered to develop an optimized environment that enables a greater complete functional recovery following mid-gap nerve repair in comparison to hollow nerve conduits alone.

Get Discount on Nerve Repair and Regeneration Market Research Study: https://www.theinsightpartners.com/discount/TIPHE100001254/

In Jan 2022, Medtronic plc received US Food and Drug Administration approval for its Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator treating chronic pain associated with diabetic peripheral neuropathy (DPN).

Thus, the active participation of market players in product innovation and development and increase in approvals of products are likely to fuel the market growth in the coming years.

Global Nerve Repair & Regeneration Market: Product Overview Based on product, the nerve repair & regeneration market is bifurcated into neurostimulation & neuromodulation devices and biomaterials. Neurostimulation & neuromodulation devices segment is further bifurcated into internal neurostimulation devices and external neurostimulation devices. Internal neurostimulation devices segment is further subsegmented into spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, and gastric electrical stimulation. External neurostimulation devices is further subsegmented into transcutaneous electrical nerve stimulation devices, transcranial magnetic stimulation devices, respiratory electrical stimulation devices. The neurostimulation and neuromodulation devices segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR in the market during the forecast period. The growing prevalence of neurological disorders, increasing application of neurostimulation and neuromodulation devices, and rapid advancements are driving the market growth of the nerve repair & regeneration market.

Buy Premium Copy of Nerve Repair and Regeneration Market Growth Report (2022-2028) at: https://www.theinsightpartners.com/buy/TIPHE100001254/

Browse Adjoining Reports: Nerve Repair Biomaterial Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Nerve Protection, Nerve Repair); Application (Epineural Nerve Repair, Perineural Nerve Repair, Group Fascicular Repair); End User (Hospitals and Clinics, Ambulatory Surgery Centers, Other) and Geography

Nerve Repair and Re-generation Biomaterials Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Nerve Conduits, Nerve Wraps, Nerve Graft, Others); Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy, Others) and Geography

Neurostimulation Devices Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Product (Deep Brain Stimulation Device, Spinal Cord Stimulation Device, Sacral Nerve Stimulation Device, Vagus Nerve Stimulation Device, and Gastric Electric Stimulation Device), Application (Pain Management, Epilepsy, Depression, Parkinson's Disease, Essential Tremor, Urinary and Fecal Incontinence, and Other Applications), and Geography

Neuromodulation Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Technology (External (Non-Invasive) Neuromodulation, and Internal Neuromodulation); Application (Chronic Pain Management, Failed Back Syndrome, Epilepsy, Tremor, Incontinence, Depression, Dystonia, Gastroparesis, Parkinson

Neuromodulation Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Internal, External); Application (SCS, DBS, VNS, SNS, GES, TENS, TMS); Biomaterial (Metallic, Polymeric, Ceramic); End-User (Hospitals, Clinics, Homecare) and Geography

Biomaterials Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Type (Metallic, Ceramic, Polymers, Natural); Application (Cardiovascular, Orthopedic, Dental, Plastic Surgery, Wound Healing, Neurological disorders, Tissue Engineering, Ophthalmology)

Biomaterials Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type ( Natural Biomaterials, Polymers Biomaterials, Ceramic Biomaterials, Metallic Biomaterials ); Application ( Orthopedic, Cardiovascular, Dental, Ophthalmology, Tissue Engineering, Other ) and Geography

Deep Brain Stimulation Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Single Channel Deep Brain Stimulator, Dual Channel Deep Brain Stimulator.); Application (Parkinson's Disease, Tremor, Depression, Alzheimer's Disease, Dystonia and Tourette Syndrome); End User (Hospitals, Research Centres) and Geography

Transcranial Magnetic Stimulator (TMS) Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Single or Paired Pulse TMS, Repetitive TMS (rTMS)); Age Group (Adults, Children); Application (Research, Diagnostic, Therapeutic), and Geography

Implantable Neurostimulation Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Technology ( spinal cord stimulation (SCS), deep brain stimulation (DBS), sacral nerve stimulation (SNS), gastric electric stimulation (GES), vagus nerve stimulation (VNS), others ); Application ( pain management, epilepsy, Parkinson's, urinary and fecal incontinence, others )

Low-Frequency Sine Wave Neurostimulation Therapy Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Percutaneous treatment, Implantation); Application (Urinary impulse, Interstitial cystitis, Idiopathic constipation) and Geography

About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us: If you have any queries about this report or if you would like further information, please contact us:

Contact Person:Sameer Joshi E-mail: sales@theinsightpartners.com Phone:+1-646-491-9876 Press Release: https://www.theinsightpartners.com/pr/nerve-repair-and-regeneration-market

Read the original:
Nerve Repair and Regeneration Market Size Worth $12,514 - GlobeNewswire

Stem Cell Therapy Global Market Report 2022: Rapid Growth in Emerging Markets & An Increase in Investments in Cell and Gene Therapies Driving…

DUBLIN--(BUSINESS WIRE)--The "Stem Cell Therapy Global Market Opportunities And Strategies To 2031" report has been added to ResearchAndMarkets.com's offering.

The global stem cell therapy market reached a value of nearly $4,019.6 million in 2021, having increased at a compound annual growth rate (CAGR) of 70.9% since 2016. The market is expected to grow from $4,019.6 million in 2021 to $10,600.2 million in 2026 at a rate of 21.4%. The market is then expected to grow at a CAGR of 11.4% from 2026 and reach $18,175.4 million in 2031.

Growth in the historic period in the stem cell therapy market resulted from rising prevalence of chronic diseases, a rise in funding from governments and private organizations, rapid growth in emerging markets, an increase in investments in cell and gene therapies, surge in healthcare expenditure, and an increase in pharmaceutical R&D expenditure. The market was restrained by low healthcare access in developing countries, limited reimbursements, and ethical concerns related to the use of embryonic stem cells in the research and development.

Going forward, increasing government support, rapid increase in the aging population, rising research and development spending, and increasing healthcare expenditure will drive market growth. Factors that could hinder the growth of the market in the future include high cost of stem cell therapy, stringent regulations imposed by regulators, and high cost of storage of stem cells.

The stem cell therapy market is segmented by type into allogeneic stem cell therapy and autologous stem cell therapy. The autologous stem cell therapy segment was the largest segment of the stem cell therapy market segmented by type, accounting for 100% of the total in 2021.

The stem cell therapy market is also segmented by cell source into adult stem cells, induced pluripotent stem cells, and embryonic stem cells. The induced pluripotent stem cells was the largest segment of the stem cell therapy market segmented by cell source, accounting for 77.2% of the total in 2021. Going forward, the adult stem cells segment is expected to be the fastest growing segment in the stem cell therapy market segmented by cell source, at a CAGR of 21.7% during 2021-2026.

The stem cell therapy market is also segmented by application into musculoskeletal disorders and wounds & injuries, cancer, autoimmune disorders, and others. The cancer segment was the largest segment of the stem cell therapy market segmented by application, accounting for 49.7% of the total in 2021. Going forward, musculoskeletal disorders and wounds & injuries segment is expected to be the fastest growing segment in the stem cell therapy market segmented by application, at a CAGR of 22.1% during 2021-2026.

The stem cell therapy market is also segmented by end-users into hospitals and clinics, research centers, and others. The hospitals and clinics segment was the largest segment of the stem cell therapy market segmented by end-users, accounting for 66.0% of the total in 2021. Going forward, hospitals and clinics segment is expected to be the fastest growing segment in the stem cell therapy market segmented by end-users, at a CAGR of 22.0% during 2021-2026.

Scope:

Markets Covered:

Key Topics Covered:

1. Stem Cell Therapy Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction

7. Stem Cell Therapy Market Characteristics

8. Stem Cell Therapy Trends And Strategies

9. Impact Of Covid-19 On Stem Cell Therapy Market

10. Global Stem Cell Therapy Market Size And Growth

11. Global Stem Cell Therapy Market Segmentation

12. Stem Cell Therapy Market, Regional And Country Analysis

13. Asia-Pacific Stem Cell Therapy Market

14. Western Europe Stem Cell Therapy Market

15. Eastern Europe Stem Cell Therapy Market

16. North America Stem Cell Therapy Market

17. South America Stem Cell Therapy Market

18. Middle East Stem Cell Therapy Market

19. Africa Stem Cell Therapy Market

20. Stem Cell Therapy Global Market Competitive Landscape

21. Stem Cell Therapy Market Pipeline Analysis

22. Key Mergers And Acquisitions In The Stem Cell Therapy Market

23. Stem Cell Therapy Market Opportunities And Strategies

24. Stem Cell Therapy Market, Conclusions And Recommendations

25. Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/3yzskj

Continue reading here:
Stem Cell Therapy Global Market Report 2022: Rapid Growth in Emerging Markets & An Increase in Investments in Cell and Gene Therapies Driving...